Novo Nordisk's ziltivekimab fails to cut heart events in ZEUS trial
Novo Nordisk's ZEUS study found ziltivekimab lowered IL-6 levels but did not reduce heart attacks, strokes or deaths. The results were presented at the AHA conference.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
STAT News reports on the results of Novo Nordisk's ZEUS study, presented at the AHA conference in Chicago. The experimental monoclonal antibody ziltivekimab did lower interleukin-6, a key inflammation marker. However, in patients with severe illness, this did not lead to fewer heart attacks, strokes or deaths compared with placebo.
After the top-line data came out, Novo Nordisk halted two other trials of the drug, HERMES and ATHENA. The decision followed a September finding by a data monitoring committee that both were unlikely to succeed.
why it matters
For investors, the setback matters because it narrows Novo Nordisk's cardiovascular pipeline beyond its core business. The effect on the stock is likely limited, but analysts are expected to factor this result into their view of the company's pipeline.
market impact
Novo Nordisk: failed ziltivekimab program weighs on expectations for its cardiovascular pipeline
- Novo Nordisk shares pressure down — failed trial removes a cardiovascular candidate from the pipeline
tags
instruments
sources
- AHA conference news: Novo Nordisk's ZEUS trial failure examined — statnews.com, 7 November 2026 at 14:36 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗